<DOC>
	<DOCNO>NCT00614393</DOCNO>
	<brief_summary>This study compare safety efficacy dalotuzumab ( MK-0646 ) combination cetuximab irinotecan treat participant wild type KRAS ( wtKRAS ) metastatic colorectal cancer ( CRC ) compare cetuximab irinotecan alone . The primary study hypothesis administration dalotuzumab combination cetuximab irinotecan participant metastatic CRC express wtKRAS genotype improve Overall Survival OR Progression-free Survival compare participant treat cetuximab irinotecan alone .</brief_summary>
	<brief_title>Study Dalotuzumab ( MK-0646 ) Combination With Cetuximab Irinotecan Metastatic Colorectal Cancer ( MK-0646-004 )</brief_title>
	<detailed_description>Dalotuzumab humanize monoclonal antibody ( mAb ) target insulin-like growth factor type 1 receptor-1 ( IGF-1R ) . Dalotuzumab may act inhibition insulin-like growth factor-1 ( IGF-1 ) -mediated cell signal cause reduction tumor growth spread antibody dependent cell-mediated cytotoxicity . In preclinical study , dalotuzumab improve activity anti-epidermal growth factor receptor ( EGFR ) mAb activity erlotinib , small molecule inhibitor EGFR . All eligible participant receive cetuximab 400 mg/m^2 infusion 120 minute follow weekly infusion cetuximab 250 mg/m^2 60-120 minute along irinotecan infusion 30-90 minute . Dosage irinotecan recent pre-study therapy . Participants assign one three treatment double-blind arm .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Participant must confirm wtKRAS CRC . Participant must previously fail irinotecan oxaliplatin contain regimen , progress within 3 month complete last line therapy objective evidence progression verify previous radiologic scan . Participant cancer treatment within 2 week first dose study drug ( ) side effect drug go certain level 2 week first dose study drug . Participant bad side effect irinotecan therapy . Participant human immunodeficiency virus ( HIV ) . Participant Hepatitis B C. Participant pregnant breast feed plan child study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>